BUSINESS
Ono Files Multiple Myeloma Treatment Kyprolis for Once-Weekly Administration Regimen
Ono Pharmaceutical said on March 19 that it has filed an application for an additional administration and dosage regimen of the proteasome inhibitor Kyprolis for IV Drip Infusion (carfilzomib) for relapsed or refractory multiple myeloma. Kyprolis is currently used for…
To read the full story
BUSINESS
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





